Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia (2012)
- Authors:
- Levin, Raquel - Universidade Federal de São Paulo (UNIFESP)
- Almeida, Valéria - Universidade Federal de São Paulo (UNIFESP)
- Peres, Fernanda Fiel - Universidade Federal de São Paulo (UNIFESP)
- Calzavara, Mariana Bendlin - Universidade Federal de São Paulo (UNIFESP)
- Silva, Neide Derci da - Universidade Federal de São Paulo (UNIFESP)
- Suiama, Mayra Akimi - Universidade Federal de São Paulo (UNIFESP)
- Niigaki, Suzie Tamie - Universidade Federal de São Paulo (UNIFESP)
- Zuardi, Antonio Waldo
- Hallak, Jaime Eduardo Cecílio
- Crippa, José Alexandre de Souza
- Abilio, Vanessa Costhek - Universidade Federal de São Paulo (UNIFESP)
- USP affiliated authors: CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; ZUARDI, ANTONIO WALDO - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP
- Unidade: FMRP
- Subjects: CANNABIS (COMPONENTES;FARMACOLOGIA); ANTAGONISMO DE DROGAS; MODELOS ANIMAIS DE DOENÇAS; ESQUIZOFRENIA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Current Pharmaceutical Design
- ISSN: 1381-6128
- Volume/Número/Paginação/Ano: v. 18, n. 32, p. 4960-4965, 2012
-
ABNT
LEVIN, Raquel et al. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design, v. 18, n. 32, p. 4960-4965, 2012Tradução . . Acesso em: 11 ago. 2024. -
APA
Levin, R., Almeida, V., Peres, F. F., Calzavara, M. B., Silva, N. D. da, Suiama, M. A., et al. (2012). Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design, 18( 32), 4960-4965. -
NLM
Levin R, Almeida V, Peres FF, Calzavara MB, Silva ND da, Suiama MA, Niigaki ST, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design. 2012 ; 18( 32): 4960-4965.[citado 2024 ago. 11 ] -
Vancouver
Levin R, Almeida V, Peres FF, Calzavara MB, Silva ND da, Suiama MA, Niigaki ST, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design. 2012 ; 18( 32): 4960-4965.[citado 2024 ago. 11 ] - Cannabidiol: an anxiolytic or an antipsychotic new drug?
- Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizopherenia: an update
- Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study
- Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus
- Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
- Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain
- Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implication for neuroprotection
- Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats
- Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system
- Cannabidiol and neuroprotection: evidence from preclinical studies
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
